ADMA BIOLOGICS, INC. current report, 21 January 2017

Full document

ADMA Biologics, Inc. - Form 8-K Summary

Business Context and Reporting Period

Date of Report: January 21, 2017
Company: ADMA Biologics, Inc. (ADMA)
Event: Entry into a Material Definitive Agreement (Master Purchase and Sale Agreement) with Biotest Pharmaceuticals Corporation (Seller) and its affiliates.
Transaction Overview: ADMA's subsidiary, ADMA BioManufacturing, LLC, agreed to acquire the therapy business of Biotest, including an FDA-licensed manufacturing facility in Boca Raton, Florida, and exclusive rights to products Nabi-HB, BIVIGAM, and CIVACIR. Biotest will retain its plasma business.

Key Financial Metrics and Transaction Terms

This filing details a strategic acquisition rather than periodic financial results. Key financial terms include:

  • Equity Consideration: ADMA will issue approximately 50% (less one share) of its post-closing capital stock to Biotest. This consists of 4,295,580 common shares (25%) and 8,591,160 non-voting convertible shares (25%).
  • Cash Consideration: Biotest will provide a $12,500,000 capital contribution to ADMA BioManufacturing, LLC.
  • Debt Financing: Biotest will fund a $15,000,000 unsecured subordinated loan to the buyer at 6% annual interest, payable semiannually, with a 5-year term.
  • Asset Valuation: The acquisition includes in-process inventory with an agreed-upon value of at least $5 million.
  • Real Estate Transfer: On January 1, 2019, ADMA will transfer its biocenters in Norcross and Marietta, Georgia, to Biotest for no additional consideration, subject to a repurchase right if Biotest ownership falls below 20% within five years.
  • Termination Fees: A fee of $2,500,000 is payable to Biotest if ADMA's board exercises a fiduciary out or fails to obtain requisite stockholder approval.

Material Changes and Strategic Shifts

The transaction represents a significant expansion of ADMA's manufacturing capabilities and product portfolio:

  • Manufacturing Capacity: Acquisition of a 126,000 square foot, FDA-licensed facility in Boca Raton, Florida.
  • Product Portfolio: Addition of FDA-licensed biologics Nabi-HB and BIVIGAM, and the investigational product CIVACIR.
  • Supply Chain: Execution of a ten-year plasma supply agreement where Biotest will sell high titer Hepatitis B plasma to ADMA.
  • Ownership Structure: Biotest will become a majority shareholder (approx. 50%) and gain the right to designate one director and one observer to ADMA's board.
  • Liability Assumption: ADMA will assume specific liabilities related to the acquired business, including product liabilities and regulatory matters (e.g., an existing FDA warning letter), excluding fraud or willful misconduct by the Seller.

Guidance, Outlook, Risks, and Contingencies

Outlook and Conditions:

  • Closing Date: Expected to close on the third business day after all conditions are met, including the expiration of the Hart-Scott-Rodino waiting period. No specific date is guaranteed.
  • Outside Date: The agreement may be terminated if not consummated by September 30, 2017.
  • Future Rights: Biotest retains a right of first offer for an exclusive license to market new plasma-based products in Europe, the Near and Middle East, and selected territories for up to 10 years post-closing.
Risks and Contingencies:
  • Regulatory Approval: Closing is contingent on regulatory reviews and the resolution of outstanding FDA issues at the Boca Raton facility.
  • Integration Risks: Risks associated with integrating operations, systems, and employees, and managing increased scale and complexity.
  • Stockholder Approval: The transaction requires stockholder approval; failure to obtain it triggers expense reimbursement to Biotest.
  • Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from predictions regarding commercialization, FDA approvals, and transaction benefits.
Unusual Items:
  • Voting Agreements: Stockholders representing approximately 50.59% of voting securities have entered into voting agreements to support the transaction and vote against alternative transactions.
  • CEO Succession: Biotest stockholders are granted rights to nominate candidates to replace the CEO in the event of death or permanent disability.

Investor Verification Checklist

  • Verify the status of the FDA warning letter issued to the Boca Raton facility and the remediation plan.
  • Review the upcoming Proxy Statement on Schedule 14A for detailed financial projections and voting procedures.
  • Confirm the dilution impact on existing shareholders given the issuance of ~50% of post-closing equity to Biotest.
  • Assess the terms of the $15 million subordinated loan and its impact on ADMA's future debt capacity.
  • Monitor the timeline for the September 30, 2017 "Outside Date" for transaction consummation.
  • Examine the specific liabilities being assumed, particularly regarding product recalls and adverse event reporting.